By Iain Gilbert
Date: Wednesday 29 Apr 2026
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that it had delivered solid revenue growth and a series of positive late‑stage trial readouts in the first quarter, reinforcing confidence in its 2030 ambitions.
| Director/PDMR Shareholding | 22-Dec-2025 | 11:00 | RNS |
| Enhertu granted BTD for post-neoadjuvant early BC | 22-Dec-2025 | 07:30 | RNS |
| Update on LATIFY Phase III trial of ceralasertib | 22-Dec-2025 | 07:00 | RNS |
| Director/PDMR Shareholding | 19-Dec-2025 | 11:00 | RNS |
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 13,948.00p |
| Change Today | 256.00p |
| % Change | 1.87 % |
| 52 Week High | 15,316.00 |
| 52 Week Low | 10,022.00 |
| Volume | 2,763,937 |
| Shares Issued | 1,550.98m |
| Market Cap | £216,331m |
| Beta | 0.00 |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Latest | Previous | |
|---|---|---|
| 2nd Interim | 1st Interim | |
| Ex-Div | 19-Feb-26 | 07-Aug-25 |
| Paid | 23-Mar-26 | 08-Sep-25 |
| Amount | 217.00¢ | 103.00¢ |
| Time | Volume / Share Price |
| 16:49 | 43,250 @ 13,948.00p |
| 16:40 | 1,779 @ 13,948.00p |
| 16:40 | 3,398 @ 13,948.00p |
| 16:40 | 303 @ 13,948.00p |
| 16:40 | 12 @ 13,948.00p |
You are here: research